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Abstract Bariatric surgery is most commonly carried out in
women of childbearing age. Whilst fertility rates are im-
proved, pregnancy following bariatric surgery poses several
challenges. Whilst rates of many adverse maternal and foetal
outcomes in obese women are reduced after bariatric surgery,
pregnancy is best avoided for 12–24 months to reduce the
potential risk of intrauterine growth retardation. Dumping
syndromes are common after bariatric surgery and can present
diagnostic and therapeutic challenges in pregnancy. Early
dumping occurs due to osmotic fluid shifts resulting from
rapid gastrointestinal food transit, whilst late dumping is char-
acterized by a hyperinsulinemic response to rapid absorption
of simple carbohydrates. Dietary measures are the mainstay of
management of dumping syndromes but pharmacotherapy
may sometimes become necessary. Acarbose is the least haz-
ardous pharmacological option for the management of post-
prandial hypoglycemia in pregnancy. Nutrient deficiencies
may vary depending on the type of surgery; it is important
to optimize the nutritional status of women prior to and during
pregnancy. Dietary management should include adequate pro-
tein and calorie intake and supplementation of vitamins and
micronutrients. A high clinical index of suspicion is required
for early diagnosis of surgical complications of prior weight
loss procedures during pregnancy, including small bowel ob-
struction, internal hernias, gastric band erosion or migration
and cholelithiasis.
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Introduction
Obesity affects a quarter of all adult women in Western
Europe and Canada, and a third in the USA [1].Whilst obesity
in general increases the risk of various weight-related disor-
ders, maternal obesity, defined as a BMI ≥ 30 kg/m2 during
pregnancy, in particular increases the risk of various pregnan-
cy complications such as miscarriage, foetal abnormality, pre-
maturity, macrosomia, dystocia, birth injury, still birth and
neonatal death, pregnancy-induced hypertension, gestational
diabetes, thrombosis, difficulty in delivery leading to higher
caesarean rates, anaesthetic complications, infection, postpar-
tum haemorrhage and maternal mortality [2–5]. Whereas life-
style and dietary measures and anti-obesity pharmacotherapy
are recommended as the primary treatment approach for obe-
sity, bariatric surgery remains the most clinically effective and
cost-effective intervention for people with morbid obesity [6,
7]. Thus, the global uptake of bariatric surgery has increased
exponentially in the past decade [8, 9], including in women of
childbearing age [10]. Thus, pregnancy following bariatric
surgery is increasingly encountered in clinical practice.
These clinical presentations pose surgical, medical and obstet-
ric challenges [2, 11, 12] requiring multidisciplinary team
management. We discuss management of common complica-
tions of bariatric surgery that may be seen in pregnancy.
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Methods
We undertook a focused, non-systematic, narrative review of
the literature with searches of the published literature in
PubMed (www.pubmed.gov) and Google Scholar (www.
scholar.google.com) with a broad range of combinations of
the medical subject headings (MeSH) terms, ‘obesity’, ‘ma-
ternal obesity’, ‘bariatric surgery’, ‘gastric bypass’, ‘gastric
band’, ‘sleeve gastrectomy’, ‘pregnancy’ and ‘fertility’;
English language articles retrieved up to May 2015 were
included.
Results
Themajority of women seeking bariatric surgery belong to the
reproductive age group [13]. Thus, fertility and pregnancy are
significant concerns following bariatric surgery.
Bariatric Surgery and Fertility
Obesity in women of childbearing age is linked with lower fer-
tility rates through associated oligo-ovulation and anovulation,
even in women with regular menstrual periods [14–16].
Polycystic ovarian syndrome (PCOS) and its associated compli-
cations are also inherently linked with weight gain. Bariatric
surgery can lead to prompt resolution of anovulation, improved
menstrual regularity and an amelioration of PCOS linked health
complications [17–20]. Overall fertility appears to improve after
bariatric surgery though data is limited [21, 22]. The extent of
weight loss following surgery may determine fertility potential
[23]. The first 12 months after bariatric surgery represent an
active catabolic state due to rapid weight loss, with gradual sta-
bilization of the body’s nutritional state in the following months.
For this reason women are generally advised to avoid pregnancy
for 12–24 months after bariatric surgery [24, 25]. This aims to
reduce the potential risk of intrauterine growth retardation during
this period whilst allowing the woman to attain the full therapeu-
tic benefit of the procedure [10, 26]. Pre-conception counselling
in this period should include consideration of non-oral contracep-
tives as the efficacy of oral contraceptive pills may be compro-
mised by unreliable absorption following bariatric surgery [27].
However, in the event that pregnancy does occur within the 12-
month period following bariatric surgery, there is limited evi-
dence that pregnancy outcomes in this situation are comparable
to those of pregnancies after the 12-month period [28].
Maternal and Foetal Outcomes
Rates of many adverse maternal and neonatal outcomes are
significantly lower in womenwho become pregnant following
bariatric surgery [4, 29, 30]. A recent large study from Sweden
compared 596 singleton pregnancies in women who had
previously undergone bariatric surgery with 2356 control
pregnancies in women matched for pre-surgery BMI, age,
parity, smoking history, educational level and delivery year
[31]; this study reported lower incidences of gestational dia-
betes and large for gestational age babies in the postbariatric
surgery women. However, rates of small for gestational age
births and shorter gestation periods were higher in the
postbariatric surgery women than in controls. There was no
difference in rates of congenital malformation between the
two groups. A recent meta-analysis of 11 cohort studies com-
pared maternal and foetal outcomes in obese women who had
undergone bariatric surgery with obese women who had not
had surgery [32]. This study also reported a lower likelihood
of gestational diabetes, hypertension and macrosomia follow-
ing bariatric surgery but increased odds of offspring being
small for gestational age; rates of caesarean section, postpar-
tum haemorrhage and preterm delivery were not significantly
different between the two groups.
Dumping Syndromes
Dumping syndromes are common after bariatric surgery and
can present diagnostic and therapeutic challenges. The patho-
physiological basis of these syndromes after bariatric surgery
is not well understood and maybe multifactorial [33].
Early Dumping Syndrome
Early dumping occurs within an hour after food and is attrib-
uted to accelerated transit of ingested meals causing osmotic
shifts in the small bowel and release of vasoactive intestinal
hormones, leading to vasomotor symptoms such as flushing,
palpitation, perspiration, tachycardia, hypotension and synco-
pe (Fig. 1). It is frequently accompanied by gastrointestinal
symptoms such as nausea, abdominal pain, borborygmi,
bloating and diarrhoea.
Management of Early Dumping Dietary measures include
advising patients to consume smaller amounts in one sitting
by dividing the recommended daily energy intake between
six meals [33]. Patients are also advised to delay any liquid
intake until at least 30 min after a meal. Lying down for
30 min after meals can prolong gastric emptying and help to
reduce vasomotor symptoms.
Late Dumping Syndrome
Late dumping or postprandial hypoglycemia occurs 1 to 3 h
after meals. It is partly incretin-mediated and is thought to occur
in response to hyperinsulinemia following rapid glucose transit
into the jejunum (Fig. 1). This results in a reactive hypoglycemia
manifesting as diaphoresis, tremulousness, poor concentration,
altered consciousness, palpitation and syncope.
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The physiological increase in insulin secretion and insulin
sensitivity that occurs in early gestation increases the risk of
hypoglycemia in women who conceive following bariatric
surgery. It is worth noting in this context that the standard oral
glucose tolerance test used to identify gestational diabetes is
frequently poorly tolerated in women who have had gastric
bypass, sleeve gastrectomy or biliopancreatic diversion proce-
dures as the rapid osmotic load of the glucose drink in the
small intestine can cause significantly distressing symptoms
from early dumping as well as profound reactive hypoglyce-
mia from late dumping. Assessment of home capillary blood
glucose (cBG) profiles and/or continuous glucose monitoring
(CGM) over 1–2 weeks around 24–28 weeks of gestation may
offer an alternative means of diagnosing gestational diabetes
that is better tolerated in this context.
Management of Late Dumping Dietary modifications are the
mainstay of management of postprandial hypoglycemia and
principally include the avoidance of refined carbohydrates in
favour of low glycemic index foods. All rapidly absorbable car-
bohydrates (for example, all sweet or sweetened foods) should be
eliminated from the diet to prevent late dumping symptoms [33].
A limited number of pharmacological agents have been used in
the treatment of postprandial hypoglycemia in non-pregnant in-
dividuals [33]. Adding pectin or guar gum to increase the viscos-
ity of food, which slows down gastric emptying, can ameliorate
symptoms in the short term [33]; however, they are poorly toler-
ated due to unpalatability.
Diazoxide Diazoxide decreases insulin release by inhibiting
voltage-sensitive calcium channels [33]. It has been used clin-
ically in the medical treatment of insulinoma, and administra-
tion of 100 to 150 mg three times daily for late dumping
symptoms has been reported anecdotally. However, reproduc-
tion studies have revealed increased foetal resorptions, foetal
skeletal anomalies and delayed parturition in rats, and skeletal
and cardiac teratogenic effects in rabbits. It also crosses the
placental barrier in animals and causes degeneration of foetal
pancreatic β cells. Safety in pregnancy has not been
established and the United States Federal Drug Agency
(FDA) has classed diazoxide in Pregnancy Category C (ani-
mal reproduction studies have shown an adverse effect on the
Fig. 1 Pathophysiology of dumping syndromes following gastric bypass
surgery and mode of action of common therapeutic agents. Reduced
gastric volume results in rapid gastric emptying (1) and rapid glucose
absorption (2), which induces a hyperinsulinemic response (3), leading
to reactive hypoglycemia 1–3 h after food (late dumping syndrome).
Rapid delivery of hyperosmolar chyme to the upper small bowel (4)
induces release of several vasoactive gut hormones (5), such as
vasoactive intestinal peptide, neurotensin, glucagon-like peptide-1
(GLP-1) and glucagon-dependent insulinotropic peptide (GIP), which
results in vasomotor symptoms 10–60 min after food (early dumping
syndrome). Agents that increase meal viscosity, such as pectin or guar
gum, may help to slow down gastric emptying. The α-glucosidase
inhibitor, acarbose, can slow down the breakdown and absorption of
food sugars. Diazoxide inhibits insulin release from β cells in the
pancreatic islets and can attenuate the hyperinsulinemic response. The
somatostatin analogue, octreotide, works at multiple levels in the upper
gastrointestinal tract, including slowing of gastric emptying and
inhibition of secretion and release of insulin and vasoactive gut
hormones, and can be useful in the treatment of intractable symptoms
of both types of dumping syndrome
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foetus, and there are no adequate and well-controlled studies
in humans, but potential benefits may warrant use of the drug
in pregnant women despite potential risks) [34]. Diazoxide
appears in cord blood when given to pregnant women and
may produce various foetal or neonatal adverse effects includ-
ing hyperbilirubinemia, thrombocytopenia, altered carbohy-
drate metabolism, alopecia and hypertrichosis lanuginosa.
Octreotide Somatostatin analogues, of which octreotide is the
most commonly studied, act by decreasing gastric emptying
rate, retarding transit through the small bowel, inhibiting re-
lease of gastrointestinal hormones, inhibiting insulin secretion
and inhibiting postprandial vasodilation [33]. The major dis-
advantages of somatostatin analogues include the need for
subcutaneous injections (which can be particularly problem-
atic with short-acting preparations), adverse effects such as
pain at injection sites, steatorrhea and gallstone formation
and substantial cost. Whilst successful long-term treatment
with somatostatin analogues in intractable postprandial hypo-
glycemia following gastric bypass surgery has been described
[35], there are no adequate studies in pregnant women.
Reproduction studies in rats and rabbits at doses up to 16 times
the highest recommended human dose based on body surface
area have shown no evidence of foetal harm due to octreotide.
However, octreotide should be used during pregnancy only if
clearly needed (FDA Pregnancy Category B: animal repro-
duction studies have failed to demonstrate a risk to the foetus,
but there are no adequate and well-controlled studies in preg-
nant women) [36]. No congenital malformations have been
reported in postmarketing data from a limited number of ex-
posed pregnancies in women with acromegaly.
Acarbose Acarbose, an intestinal α-glycosidase inhibitor, de-
lays digestion and absorption of carbohydrates in the small
intestine, and results in improved glucose tolerance, decreased
release of gastrointestinal hormones and reduced incidence of
hypoglycemia. Because of its mechanism of action, acarbose
when administered alone does not cause hypoglycemia in the
fasted state. Acarbose treatment often results in bloating, flat-
ulence or diarrhoea, as the unabsorbed carbohydrates undergo
bacterial fermentation in the small intestine [33]. Rodent stud-
ies of acarbose have shown no evidence of impaired fertility or
harm to the foetus using the equivalent of nine times the ex-
posure in humans based on blood drug levels. Studies in rab-
bits have shown no evidence of embryotoxicity at 10 times or
teratogenicity at 32 times the dose in man based on body
surface area. However, there are no adequate and well-
controlled studies of acarbose in pregnant women (FDA
Pregnancy Category B) [37]. Acarbose is a recognized treat-
ment for postprandial hypoglycemia in non-pregnant individ-
uals [33] and has separately been explored in gestational dia-
betes. Our Case Study (see box) is the first report in the
published literature of the successful use of acarbose in post-
prandial hypoglycemia in pregnancy following bariatric
surgery.
Continuous Enteral Feeding Continuous enteral feeding via
a nasogastric tube or a feeding jejunostomy to avoid dumping
symptoms that are triggered by meal ingestion has been de-
scribed in the management of refractory dumping syndrome
[33]. However, this is a rather invasive intervention, with a
major effect on daily life, and to our knowledge has not been
reported in the management of dumping syndromes in
pregnancy.
Case study
A 25-year-old woman with morbid obesity, acanthosis nigricans, poly-
cystic ovarian syndrome, oligomenorrhoea and primary infertility and
childhood-onset absence seizures underwent Roux-en-Y gastric by-
pass (RYGB) surgery. Ayear later, her weight had reduced from 125 to
78 kg and body mass index (BMI) from 47 6 to 29 7 kg/m2. This was
accompanied by a remarkable resolution of acanthosis nigricans and
restoration of normal menstruation, and she soon became pregnant
spontaneously. She started experiencing symptomatic hypoglycemic
episodes 1 to 3 h after food early in pregnancy. Fingerprick capillary
blood glucose (cBG) monitoring and continuous glucose monitoring
(CGM; MiniMed Paradigm 522, Medtronic®) confirmed non-fasting,
postprandial hypoglycemia, with glucose levels of less than 2.2 mmol/
L. Fasting plasma glucose was 4 2 mmol/L, serum insulin 51 IU/L and
C-peptide 418 pmol/L. Urine tested negative for sulphonylureas.
Serum cortisol, thyroid hormones and vitamin and micronutrient levels
were satisfactory. Despite dietary management with a low glycemic
index (GI) diet postprandial hypoglycemia increased in severity and
frequency, raising concerns of the risk of maternal neuroglycopenia
and foetal hypoglycemia. After careful consideration of further options
of management, she was commenced on acarbose in incremental doses
up to 100 mg three times daily in the second trimester. Acarbose was
well tolerated with significant reduction in hypoglycemia frequency
and severity on cBG and CGM. She proceeded to term and delivered a
healthy girl who is developing normally. Magnetic resonance imaging
of the pancreas postdelivery revealed no abnormalities, and there was
no further significant hypoglycemia on cBG and CGM. She went on to
have a second pregnancy 2 years later. She again experienced hypo-
glycemic episodes, typically associated with consumption of high GI
foods but not with low GI foods. The hypoglycemia was not as severe
or as frequent as in the first pregnancy andwas managed by lowGI diet
without resorting to acarbose. She proceeded to term and delivered a
healthy boy who is also developing normally.
Nutrient Deficiencies
It is important to optimize the nutritional status of women
prior to and following bariatric surgery [2, 38]. Nutritional
deficiencies may vary depending on the type of surgery. For
example, nutrient deficiencies may be minimal after gastric
banding, which is a primarily restrictive procedure. Gastric
bypass, the most common type of mixed restrictive and
malabsorptive bariatric surgery worldwide, may be associated
with deficiencies of iron, vitamin B12, calcium, vitamin D and
other fat soluble vitamins, and trace elements. Sleeve
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gastrectomy, a predominantly restrictive procedure, is associ-
ated with the above deficiencies to a lesser extent. The less
common duodenal switch and biliopancreatic diversion pro-
cedures are associated with significant malabsorption of mac-
ronutrients including protein and fat, and micronutrients and
vitamins such as vitamins A, D and B12, calcium, iron, sele-
nium, zinc and copper. It is crucial that people who have
undergone bariatric surgery, women of childbearing age in
particular, have dietary supplementation of multivitamins
and micronutrients and specialist review regularly for moni-
toring of deficiencies [38, 39]. Care must be taken to ensure
that any prescribed supplements and medications for women
planning a family are safe in pregnancy. Retinol-based vita-
min A products are best avoided in the first 12 weeks of
pregnancy due to their teratogenic potential. For women found
to have vitamin A deficiency, the beta carotene form of vita-
min A is preferred. Protein intake should be maintained above
60 g per day [38, 40], and caloric restriction and active weight
loss during pregnancy are not advisable even if overweight or
obese. Gastric bands may need to be partially or completely
deflated to allow appropriate nutritional intake and ameliorate
pregnancy-related gastrointestinal symptoms.
Surgical Complications
During the antenatal period, care must be taken to distinguish
complications related to bariatric surgery from physiological
manifestations of pregnancy. A history of bariatric surgery
should not influence the course of labour and delivery.
However, whilst bariatric surgery is not in itself an indication
for caesarean section, rates of caesarean section do appear to
be higher than average in women who have had bariatric sur-
gery. Whilst nausea, vomiting and abdominal pain are com-
mon in normal pregnancies, in the context of bariatric surgery
theymay also occasionally represent surgical complications of
prior bariatric surgery.
Notable surgical complications during pregnancy of previ-
ous weight loss procedures could include small bowel ob-
struction, internal hernias, gastric band erosion or migration
and cholelithiasis [29, 41]. Small bowel obstruction is a well-
recognized life-threatening late, albeit rare, complication of
bariatric surgery, principally Roux-en-Y gastric bypass and
commonly results from internal hernias and sometimes from
volvulus or intussusceptions [4, 26]. The clinical presentation
of early small bowel obstruction without bowel necrosis can
be subtle [26]. Patients typically complain of crampy pain in
the left upper quadrant or epigastric region that may radiate to
the back. Vital signs, physical examination (barring tender-
ness over the area of pain) and laboratory studies may be
normal. The generally mild signs and symptoms may be mis-
taken for common and benign pregnancy-related complaints.
Thus, the patient’s surgical history of bariatric surgery and
high clinical index of suspicion are required for early detection
of small bowel obstruction. Tachycardia, abdominal dis-
tension, and elevated white blood cell counts, liver en-
zymes, amylase or lipase levels should raise concerns of
bowel necrosis or perforation. When a pregnant patient
with a history of bariatric surgery and abdominal com-
plaints fails to respond as expected to appropriate treat-
ment of the presumptive cause, she should be expedi-
tiously reassessed, preferably in a centre with specialist
bariatric expertise.
Conclusion
In summary, bariatric surgery in women of childbear-
ing age can present clinical challenges in subsequent
pregnancies. Although rates of adverse maternal and
foetal outcomes in obese women are reduced after
bariatric surgery, pregnancy is best avoided for 12–
24 months to reduce the risk of intrauterine growth
retardation. Dumping syndromes occur not infrequent-
ly and need to be distinguished from common symp-
toms of a normal pregnancy, and specialist bariatric
expertise should be sought where required. Dietary
measures are the mainstay of management of dumping
syndromes but pharmacotherapy may sometimes be-
come necessary. Acarbose is the least hazardous phar-
macological option for the management of late
dumping/postprandial hypoglycemia in pregnancy.
Nutrient deficiencies may vary depending on the type
of surgery; it is important to optimize the nutritional
status of women prior to and during pregnancy, in-
cluding adequate protein and calorie intake and sup-
plementation of vitamins and micronutrients. Finally,
early diagnosis of surgical complications of prior
weight loss procedures during pregnancy requires a high
clinical index of suspicion and prompt referral to a specialist
bariatric centre.
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